Literature DB >> 24676675

Silent (clinically nonfunctioning) pituitary adenomas.

Sarah E Mayson1, Peter J Snyder.   

Abstract

Silent, or clinically nonfunctioning, pituitary adenomas can arise from any anterior pituitary cell type. Some are "clinically silent" in that they result in a supranormal serum concentration of the hormonal product of the cell type from which the adenoma arose but do not cause the clinical manifestations typical of excessive levels of that hormone. Others are "totally silent" in that they result in neither hormonal excess nor clinical manifestations. Gonadotroph and null cell adenomas are the most prevalent types and are typically silent. Somatotroph and corticotroph adenomas typically cause clinical syndromes but occasionally are clinically or totally silent. Those that are silent are usually larger and grow more aggressively than those that cause clinical syndromes. Silent adenomas are usually not discovered until they become very large and cause neurologic defects, such as visual impairment, but are also often discovered incidentally when neuroimaging is performed for another reason. Silent adenomas may become, rarely, clinically apparent over time. The diagnosis of a silent pituitary adenoma begins with the detection of a sellar mass by MRI. Biochemical testing can identify the adenoma cell type in those that are clinically silent. Silent adenomas that cause neurologic deficits require transsphenoidal surgery, but those that do not can be followed by MRI. Residual or recurrent disease is treated by radiation therapy, which is usually effective in preventing further growth but results in hormonal deficiencies in about half of patients. Dopamine agonists and somatostatin analogs are usually ineffective, but occasionally have been associated with reduced adenoma size.

Entities:  

Mesh:

Year:  2014        PMID: 24676675     DOI: 10.1007/s11060-014-1425-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  55 in total

1.  Incidence of pituitary adenomas in Northern Finland in 1992-2007.

Authors:  Antti Raappana; John Koivukangas; Tapani Ebeling; Tapio Pirilä
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

2.  The silent corticotropinoma: is clinical diagnosis possible?

Authors:  B Ambrosi; P Colombo; D Bochicchio; M Bassetti; B Masini; G Faglia
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

3.  Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study.

Authors:  Alessandra Fusco; Antonella Giampietro; Antonio Bianchi; Vincenzo Cimino; Francesca Lugli; Serena Piacentini; Margherita Lorusso; Anna Tofani; Germano Perotti; Libero Lauriola; Carmelo Anile; Giulio Maira; Alfredo Pontecorvi; Laura De Marinis
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

4.  Long-term outcomes after gamma knife stereotactic radiosurgery for nonfunctional pituitary adenomas.

Authors:  Kyung-Jae Park; Hideyuki Kano; Phillip V Parry; Ajay Niranjan; John C Flickinger; L Dade Lunsford; Douglas Kondziolka
Journal:  Neurosurgery       Date:  2011-12       Impact factor: 4.654

5.  The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Paolo Cappabianca; Monica De Leo; Antongiulio Faggiano; Gaetano Lombardi; Leo J Hofland; Steven W J Lamberts; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

Review 6.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

7.  Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.

Authors:  T Lohmann; C Trantakis; M Biesold; S Prothmann; S Guenzel; R Schober; R Paschke
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

8.  A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.

Authors:  Shozo Yamada; Kenichi Ohyama; Manabu Taguchi; Akira Takeshita; Koji Morita; Koji Takano; Toshiaki Sano
Journal:  Neurosurgery       Date:  2007-09       Impact factor: 4.654

9.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

10.  Recognition of gonadotroph adenomas in women.

Authors:  L Daneshdoost; T A Gennarelli; H M Bashey; P J Savino; R C Sergott; T M Bosley; P J Snyder
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

View more
  14 in total

Review 1.  Functional Gonadotroph Adenomas: Case Series and Report of Literature.

Authors:  David J Cote; Timothy R Smith; Courtney N Sandler; Tina Gupta; Tejus A Bale; Wenya Linda Bi; Ian F Dunn; Umberto De Girolami; Whitney W Woodmansee; Ursula B Kaiser; Edward R Laws
Journal:  Neurosurgery       Date:  2016-12       Impact factor: 4.654

2.  Predictive factors of visual function recovery after pituitary adenoma resection: a literature review and Meta-analysis.

Authors:  Min Sun; Zhi-Qiang Zhang; Chi-Yuan Ma; Sui-Hua Chen; Xin-Jian Chen
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

Review 3.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas.

Authors:  Georgia Ntali; John A Wass
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

5.  FOLLICLE-STIMULATING HORMONE-PRODUCING PITUITARY ADENOMA: A CASE REPORT AND REVIEW OF THE LITERATURE.

Authors:  Sonal Patel; Donato Pacione; Ilene Fischer; Ekrem Maloku; Nidhi Agrawal
Journal:  AACE Clin Case Rep       Date:  2019-04-25

Review 6.  Histopathological classification of non-functioning pituitary neuroendocrine tumors.

Authors:  Emilija Manojlovic-Gacic; Britt Edén Engström; Olivera Casar-Borota
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

7.  Follicle-Stimulating Hormone-Secreting Pituitary Adenoma Inducing Spontaneous Ovarian Hyperstimulation Syndrome, Treatment Using In Vitro Fertilization and Embryo Transfer: A Case Report.

Authors:  Xiaofang Du; Wen Zhang; Xingling Wang; Xiaona Yu; Zhen Li; Yichun Guan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-24       Impact factor: 5.555

8.  Functional Characteristics of Multipotent Mesenchymal Stromal Cells from Pituitary Adenomas.

Authors:  Kaspars Megnis; Ilona Mandrika; Ramona Petrovska; Janis Stukens; Vita Rovite; Inga Balcere; Laima Sabine Jansone; Raitis Peculis; Valdis Pirags; Janis Klovins
Journal:  Stem Cells Int       Date:  2016-06-02       Impact factor: 5.443

9.  Function of cell-cycle regulators in predicting silent pituitary adenoma progression following surgical resection.

Authors:  Sung Hyun Park; Ji Hwan Jang; Young Min Lee; Joon Soo Kim; Kyu Hong Kim; Young Zoon Kim
Journal:  Oncol Lett       Date:  2017-10-02       Impact factor: 2.967

10.  A novel "total pituitary hormone index" as an indicator of postoperative pituitary function in patients undergoing resection of pituitary adenomas.

Authors:  Shousen Wang; Biao Li; Chenyu Ding; Deyong Xiao; Liangfeng Wei
Journal:  Oncotarget       Date:  2017-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.